Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

Clinical trial NCT07496229 · RECRUITING

Trial details

NCT number: NCT07496229
Sponsor: Dizal Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

T-cell Lymphomas

Start date: 2026-04-15
Primary completion: 2029-09-01
Enrollment: 165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.